Review article · 2025 · Open access
Emerging nanoparticle-based therapies for pancreatic cancer: Current clinical landscape
Advanced Drug Delivery Reviews, 229, 115760 · Published 12 December 2025 · DOI 10.1016/j.addr.2025.115760
In brief
“Emerging nanoparticle-based therapies for pancreatic cancer: Current clinical landscape” is a 2025 review article by Ainara Salgado-Pascual and 3 co-authors, published in Advanced Drug Delivery Reviews. OpenAlex counts 18 citations as of 17 November 2026, which puts it in the top 1% of works published in 2025 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Advanced Drug Delivery Reviews.
- Citations
- 18
- Most cited in
- 2026 (18)
- Field-weighted impact
- 0.81
- References
- 182
- Authors
- 4
Abstract
Pancreatic cancer, particularly ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal subtypes due to late diagnosis, the absence of early biomarkers, and the presence of a complex tumor microenvironment (TME). This TME is characterized by a dense desmoplastic stroma, hypovascularization, immunosuppression, and an acidic extracellular pH. All of these factors hinder the delivery and efficacy of conventional therapies, especially in advanced stages. Nanoparticles (NPs), including liposomes, polymeric micelles, albumin-bound particles and lipid nanoparticles, have emerged as a promising tool for overcoming TME barriers, and enhance drug delivery in tumor while minimizing systemic toxicity. NPs can exploit mechanisms such as the Enhanced Permeability and Retention (EPR) effect and active targeting. Clinically approved NPs such as Nab-Paclitaxel and liposomal Irinotecan have demonstrated improved pharmacokinetics and therapeutic benefits in PDAC. Furthermore, ongoing clinical trials are exploring novel NP-based strategies such as gene delivery, radiosensitization, immunomodulation and ferroptosis induction. Despite these promising advances, significant challenges remain, including poor tumor penetration, heterogeneity in EPR, and immune recognition of NPs leading to their clearance from bloodstream before reaching the tumor. Innovative solutions such as biomimetic coatings, stimuli-responsive systems and personalized formulations, are being evaluated to enhance NP performance. Standardization of NP characterization and data reporting are essential to accelerating clinical translation. The integration of artificial intelligence and machine learning could further optimize NP design and patient stratification. Overall, nanotechnology represents a crucial frontier of research for developing more effective and personalized pancreatic cancer treatments.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Salgado-Pascual, A., Zalba, S., Lasarte, J. J., & Garrido, M. J. (2025). Emerging nanoparticle-based therapies for pancreatic cancer: Current clinical landscape. Advanced Drug Delivery Reviews, 229, 115760. https://doi.org/10.1016/j.addr.2025.115760
MLA 9
Salgado-Pascual, Ainara, et al. “Emerging nanoparticle-based therapies for pancreatic cancer: Current clinical landscape.” Advanced Drug Delivery Reviews, vol. 229, 2025, p. 115760. https://doi.org/10.1016/j.addr.2025.115760.
Chicago
Salgado-Pascual, Ainara, Sara Zalba, Juan José Lasarte, and María J. Garrido. 2025. “Emerging nanoparticle-based therapies for pancreatic cancer: Current clinical landscape.” Advanced Drug Delivery Reviews 229: 115760. https://doi.org/10.1016/j.addr.2025.115760.
Harvard
Salgado-Pascual, A. et al. (2025) ‘Emerging nanoparticle-based therapies for pancreatic cancer: Current clinical landscape’, Advanced Drug Delivery Reviews, 229, p. 115760. doi:10.1016/j.addr.2025.115760.
IEEE
A. Salgado-Pascual, S. Zalba, J. J. Lasarte, and M. J. Garrido, “Emerging nanoparticle-based therapies for pancreatic cancer: Current clinical landscape,” Advanced Drug Delivery Reviews, vol. 229, p. 115760, 2025, doi: 10.1016/j.addr.2025.115760.
BibTeX
@article{salgadopascual2025emerging,
title = {{Emerging nanoparticle-based therapies for pancreatic cancer: Current clinical landscape}},
author = {Salgado-Pascual, Ainara and Zalba, Sara and Lasarte, Juan José and Garrido, María J.},
journal = {Advanced Drug Delivery Reviews},
year = {2025},
volume = {229},
pages = {115760},
doi = {10.1016/j.addr.2025.115760},
url = {https://doi.org/10.1016/j.addr.2025.115760}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- pancreatic ductal adenocarcinoma
- nanoparticle drug delivery
- tumor microenvironment
- liposomes
- polymeric micelles
- lipid nanoparticles
- enhanced permeability and retention effect
- active targeting
Work with this paper
Most-cited papers in Materials Science
- Electric Field Effect in Atomically Thin Carbon FilmsKostya S. Novoselov, Andre K. Geim, Sergey V. Morozov and 5 more · Science · 2004 · 67,474 citations
- Revised effective ionic radii and systematic studies of interatomic distances in halides and chalcogenidesROBERT D. SHANNON · Acta Crystallographica Section A · 1976 · 66,944 citations
- Ab initio molecular dynamics for liquid metalsGeorg Kresse, J. Häfner · Physical review. B, Condensed matter · 1993 · 46,320 citations
- Helical microtubules of graphitic carbonSumio Iijima · Nature · 1991 · 43,639 citations
- The rise of grapheneAndre K. Geim, Kostya S. Novoselov · Nature Materials · 2007 · 40,328 citations
Questions about this paper
How do I cite this paper in APA style?
Salgado-Pascual, A., Zalba, S., Lasarte, J. J., & Garrido, M. J. (2025). Emerging nanoparticle-based therapies for pancreatic cancer: Current clinical landscape. Advanced Drug Delivery Reviews, 229, 115760. https://doi.org/10.1016/j.addr.2025.115760
How many times has this paper been cited?
18 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Advanced Drug Delivery Reviews: sign in and open the full text from this page.
Who wrote this paper?
Ainara Salgado-Pascual, Sara Zalba, Juan José Lasarte, María J. Garrido.
What is the DOI of this paper?
10.1016/j.addr.2025.115760, permanently at https://doi.org/10.1016/j.addr.2025.115760. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.